• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital

    6/2/25 8:34:00 AM ET
    $BLUE
    $CG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Investment Managers
    Finance
    Get the next $BLUE alert in real time by email

    New management, led by David Meek, is committed to rapidly scaling access to lifechanging gene therapies

    Significant capital commitment from Carlyle and SK Capital will enable bluebird to grow and accelerate patient access

    bluebird will focus on expanding manufacturing capacity and improving the treatment experience for patients and providers

    bluebird bio (NASDAQ:BLUE) ("bluebird"), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by global investment firms Carlyle (NASDAQ:CG) and SK Capital Partners, LP ("SK Capital"). With the closing of the transaction, bluebird's common stock has ceased trading and will no longer be publicly listed. Carlyle and SK Capital have provided significant primary capital to support and scale bluebird's commercial delivery of gene therapies for patients with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy.

    David Meek, who became Chief Executive Officer of bluebird at close, said, "Today marks the beginning of a new era for bluebird as its go-forward financial backing and leadership team will better enable all stakeholders to realize the full potential of our revolutionary therapies. Historically, bluebird has excelled as a scientific innovator and should be very proud of the many achievements it has delivered to patients. Our vision is to further that legacy of scientific excellence while improving the commercial execution of our approved products to rapidly expand access to lifechanging gene therapies."

    "We are excited to back bluebird in partnership with SK Capital. We believe providing bluebird the necessary funding along with the new leadership team will help bluebird realize its full potential," said Joe Bress, Carlyle Partner and Global Co-Head of Healthcare. Bali Muralidhar, Co-Managing Partner and Chief Investment Officer & COO of Abingworth, Carlyle's life sciences investment franchise, added, "There is an incredible opportunity to bring bluebird's groundbreaking therapies to more patients in need, and we look forward to advancing bluebird in its mission."

    "SK Capital looks forward to partnering with David and his team as well as Carlyle to scale bluebird's pioneering gene therapies that can make a lifechanging difference for patients around the world," said Aaron Davenport, Managing Director at SK Capital, adding, "We believe our deep collective experience in manufacturing and commercializing therapies can help drive the next chapter of bluebird's growth."

    Incoming Team Bolsters Commercial Gene Therapy Experience

    The company's momentum is reinforced by a deeply experienced management team, led by CEO David Meek. David brings more than 30 years of leadership in life sciences, including as CEO of Mirati Therapeutics and Ipsen. David is joined by Tom Klima as Chief Commercial & Operating Officer, Debasish Roychowdhury, M.D., as Chief Medical Officer, Wendy DiCicco as Chief Financial Officer, and Ellen Forest as Chief People Officer. Additional details are available at https://www.bluebirdbio.com/about-us/leadership.

    From Scientific Breakthroughs to Delivery at Scale

    With the transaction now closed, bluebird is prioritizing expanding its manufacturing infrastructure, streamlining the patient journey, supporting treatment centers, and strengthening its payer partnerships. The acquisition provides the strategic and financial backing needed to meet rising demand and drive commercial and operational excellence across the organization.

    "bluebird has demonstrated what's possible through effective gene therapy," David added. "Now we will build the ecosystem to ensure every patient who needs these therapies can access them."

    About bluebird bio

    bluebird bio is a commercial-stage biotherapeutics company focused on developing and delivering gene therapies for severe genetic diseases. With more than a decade of scientific leadership in gene therapy and three FDA-approved therapies for sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy, the company is committed to ensuring access, reliability, and patient-centered care. bluebird is headquartered in Somerville, Massachusetts.

    About Carlyle

    Carlyle (NASDAQ:CG) is a global investment firm with deep industry expertise that deploys private capital across its business and conducts its operations through three business segments: Global Private Equity, Global Credit and Carlyle AlpInvest. With $453 billion of assets under management as of March 31, 2025, Carlyle's purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest. Carlyle employs more than 2,300 people in 29 offices across four continents. Further information is available at www.carlyle.com. Follow Carlyle on X @OneCarlyle and LinkedIn at The Carlyle Group.

    About SK Capital

    SK Capital is a transformational private investment firm with a disciplined focus on the life sciences, specialty materials, and ingredients sectors. The firm seeks to build resilient, sustainable, and growing businesses that create substantial long-term value. SK Capital aims to utilize its industry, operating, and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth, and profitability, as well as lower operating risk. SK Capital currently has approximately $10 billion in assets under management as of December 31, 2024. For more information, please visit www.skcapitalpartners.com.

    Forward Looking Statement

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on historical performance and current expectations and projections about bluebird's future goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond bluebird's control and could cause bluebird's future goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect bluebird bio's business, particularly those identified in the risk factors discussion in bluebird bio's Annual Report on Form 10-K for the year ended December 31, 2024, as updated by its subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC. These risks and uncertainties include, but are not limited to: the risk that the efficacy and safety results from bluebird's prior and ongoing clinical trials will not continue or be seen in the commercial context; the risk that there is not sufficient patient demand or payer reimbursement to support continued commercialization of bluebird's products; the risk of insertional oncogenic or other safety events associated with lentiviral vector, drug product, or myeloablation, including the risk of hematologic malignancy; and the risk that bluebird's products will not be successfully commercialized. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, bluebird bio undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250602288470/en/

    Bluebird

    Courtney O'Leary

    +1 (978) 621-7347

    [email protected]

    Carlyle

    Brittany Berliner

    +1 (212) 813-4839

    [email protected]

    SK Capital

    Ben Dillon

    +1 (646) 278-1353

    [email protected]

    Get the next $BLUE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLUE
    $CG

    CompanyDatePrice TargetRatingAnalyst
    The Carlyle Group Inc.
    $CG
    7/10/2025$65.00Neutral → Buy
    Citigroup
    The Carlyle Group Inc.
    $CG
    5/14/2025$56.00Hold → Buy
    TD Cowen
    The Carlyle Group Inc.
    $CG
    3/19/2025Outperform → Perform
    Oppenheimer
    bluebird bio Inc.
    $BLUE
    2/24/2025Underweight → Neutral
    Analyst
    bluebird bio Inc.
    $BLUE
    2/24/2025$29.00Overweight
    Analyst
    The Carlyle Group Inc.
    $CG
    1/3/2025$60.00Peer Perform → Outperform
    Wolfe Research
    bluebird bio Inc.
    $BLUE
    11/18/2024Neutral → Underweight
    Analyst
    bluebird bio Inc.
    $BLUE
    11/15/2024Neutral → Underweight
    JP Morgan
    More analyst ratings

    $BLUE
    $CG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Conway William E Jr gifted 2,000,000 shares, decreasing direct ownership by 7% to 26,999,644 units (SEC Form 4)

    4 - Carlyle Group Inc. (0001527166) (Issuer)

    9/5/25 5:05:14 PM ET
    $CG
    Investment Managers
    Finance

    Chief Operating Officer Lobue Lindsay was granted 496 shares, increasing direct ownership by 0.10% to 476,225 units (SEC Form 4)

    4 - Carlyle Group Inc. (0001527166) (Issuer)

    8/29/25 4:55:04 PM ET
    $CG
    Investment Managers
    Finance

    General Counsel Ferguson Jeffrey W. was granted 744 shares, increasing direct ownership by 0.10% to 753,999 units (SEC Form 4)

    4 - Carlyle Group Inc. (0001527166) (Issuer)

    8/29/25 4:55:10 PM ET
    $CG
    Investment Managers
    Finance

    $BLUE
    $CG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 17, 2022 - FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

    For Immediate Release: August 17, 2022 Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.  “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing

    8/17/22 2:12:27 PM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BLUE
    $CG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Carlyle Secured Lending, Inc. Prices Public Company Offering of $300 Million 5.750% Unsecured Notes Due 2031

    NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (NASDAQ:CGBD) (the "Company") today announced that it has priced an underwritten public offering of $300 million in aggregate principal amount of 5.750% unsecured notes due 2031 (the "Notes"). The Notes will mature on February 15, 2031 and may be redeemed in whole or in part at the Company's option at the applicable redemption price. The offering is expected to close on October 7, 2025, subject to customary closing conditions. The Company intends to use the net proceeds from this offering to repay outstanding debt including the Company's revolving credit facility (which the Company intends to use to repay its subsi

    9/30/25 5:01:04 PM ET
    $CG
    $CGBD
    Investment Managers
    Finance
    Finance: Consumer Services

    Acentra Health's Dr. Ryan Bosch Named a 2025 Innovator in Health Care by Washington Business Journal

    MCLEAN, Va., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company committed to accelerating better health outcomes for its clients and the populations they serve, today announced that its Chief Health and Informatics Officer, Ryan Bosch, MD, has been named a 2025 Innovator in Health Care by the Washington Business Journal. The annual award recognizes Greater Washington's top clinical and business leaders who are solving healthcare's biggest challenges through innovative technology, vision, talent, and care for the region's diverse population. A practicing internal medicine physician, U.S. Air Force veteran, and nationally recognized inf

    9/30/25 9:33:00 AM ET
    $CG
    Investment Managers
    Finance

    Resonetics® Acquires Eden Holdings, Adding Injection Molding to its Capabilities

    Acquisition adds precision micro-molding, insert molding, and advanced machining and tooling to Resonetics' portfolio of precision manufacturing capabilities. NASHUA, N.H., Sept. 29, 2025 /PRNewswire/ -- Resonetics announced today that it has acquired Eden Holdings (Eden), comprising both Eden Manufacturing and Eden Tool, a precision manufacturer specializing in injection molding and micro machining solutions for critical medical devices. The acquisition adds micro-molding, insert-molding, and advanced machining and tooling, complementing Resonetics' established metal processing capabilities, while also expanding the Swiss machining and EDM machining offerings. These additions enhance Resone

    9/29/25 8:00:00 AM ET
    $CG
    Investment Managers
    Finance

    $BLUE
    $CG
    SEC Filings

    View All

    The Carlyle Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - Carlyle Group Inc. (0001527166) (Filer)

    9/19/25 4:16:41 PM ET
    $CG
    Investment Managers
    Finance

    SEC Form 8-K filed by The Carlyle Group Inc.

    8-K - Carlyle Group Inc. (0001527166) (Filer)

    9/16/25 8:12:26 PM ET
    $CG
    Investment Managers
    Finance

    SEC Form FWP filed by The Carlyle Group Inc.

    FWP - Carlyle Group Inc. (0001527166) (Subject)

    9/16/25 5:03:31 PM ET
    $CG
    Investment Managers
    Finance

    $BLUE
    $CG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Carlyle Group upgraded by Citigroup with a new price target

    Citigroup upgraded Carlyle Group from Neutral to Buy and set a new price target of $65.00

    7/10/25 8:23:02 AM ET
    $CG
    Investment Managers
    Finance

    Carlyle Group upgraded by TD Cowen with a new price target

    TD Cowen upgraded Carlyle Group from Hold to Buy and set a new price target of $56.00

    5/14/25 8:48:54 AM ET
    $CG
    Investment Managers
    Finance

    Carlyle Group downgraded by Oppenheimer

    Oppenheimer downgraded Carlyle Group from Outperform to Perform

    3/19/25 8:14:15 AM ET
    $CG
    Investment Managers
    Finance

    $BLUE
    $CG
    Leadership Updates

    Live Leadership Updates

    View All

    New Medicaid Alliance to Tackle AI Safety and Standards Across States

    MCLEAN, Va., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better health outcomes for its clients and the populations they serve, today announced the launch of the Safe AI in Medicaid Alliance (SAMA), a collaborative initiative uniting Medicaid leaders, policy experts, and technology innovators to develop safe and responsible Medicaid-focused frameworks for artificial intelligence (AI) adoption and use. Created with input and participation from the Washington State Health Care Authority (HCA), the Arizona Health Care Cost Containment System (AHCCCS), Amazon Web Services (AWS), McKinsey & Co., Arcadia, an

    9/9/25 9:33:00 AM ET
    $CG
    Investment Managers
    Finance

    Acentra Health Names Marnie Keogh as Senior Vice President of Marketing

    MCLEAN, Va., July 21, 2025 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial healthcare clients and the populations they serve, announced today that Marnie Keogh has joined the company as Senior Vice President of Marketing. In this role, Keogh will lead the company's integrated marketing strategy, driving initiatives across brand development, digital marketing, thought leadership, and go-to-market campaigns. "Marnie brings a distinguished career in healthcare marketing and communications, with a proven ability to drive brand transformation, operational excellence, and digit

    7/21/25 9:47:00 AM ET
    $CG
    Investment Managers
    Finance

    SS&C Technologies to Acquire Calastone

    SS&C Technologies Holdings, Inc. (NASDAQ:SSNC) today announced a definitive agreement to acquire Calastone, the largest global funds network and leading provider of technology solutions to the wealth and asset management industries, from global investment firm Carlyle. The purchase price is approximately £766 million (approximately US $1.03 billion), subject to certain adjustments. Headquartered in London, Calastone operates the largest global funds network, connecting more than 4,500 of the world's leading financial organizations across 57 markets. The acquisition is expected to close in Q4 2025, subject to regulatory approvals. SS&C expects the acquisition to be accretive within 12 mont

    7/21/25 4:00:00 AM ET
    $CG
    $SSNC
    Investment Managers
    Finance
    Computer Software: Prepackaged Software
    Technology

    $BLUE
    $CG
    Financials

    Live finance-specific insights

    View All

    Resonetics® Acquires Eden Holdings, Adding Injection Molding to its Capabilities

    Acquisition adds precision micro-molding, insert molding, and advanced machining and tooling to Resonetics' portfolio of precision manufacturing capabilities. NASHUA, N.H., Sept. 29, 2025 /PRNewswire/ -- Resonetics announced today that it has acquired Eden Holdings (Eden), comprising both Eden Manufacturing and Eden Tool, a precision manufacturer specializing in injection molding and micro machining solutions for critical medical devices. The acquisition adds micro-molding, insert-molding, and advanced machining and tooling, complementing Resonetics' established metal processing capabilities, while also expanding the Swiss machining and EDM machining offerings. These additions enhance Resone

    9/29/25 8:00:00 AM ET
    $CG
    Investment Managers
    Finance

    Carlyle Prices $800 Million Senior Notes Offering

    WASHINGTON, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Global investment firm Carlyle (NASDAQ:CG) priced its offering of $800 million aggregate principal amount of 5.050% senior notes due 2035. The notes will be fully and unconditionally guaranteed by Carlyle's indirect subsidiaries Carlyle Holdings I L.P., Carlyle Holdings II L.L.C., Carlyle Holdings III L.P., and CG Subsidiary Holdings L.L.C. The offering is expected to close on September 19, 2025, subject to customary closing conditions. Carlyle intends to use the net proceeds from the sale of the notes for general corporate purposes. Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC

    9/16/25 4:56:00 PM ET
    $CG
    Investment Managers
    Finance

    Carlyle Announces Senior Notes Offering

    WASHINGTON, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Global investment firm Carlyle (NASDAQ:CG) today announced its intention to offer, subject to market and other conditions, senior notes. The notes will be fully and unconditionally guaranteed by Carlyle's indirect subsidiaries Carlyle Holdings I L.P., Carlyle Holdings II L.L.C., Carlyle Holdings III L.P., and CG Subsidiary Holdings L.L.C. Carlyle intends to use the net proceeds from the sale of the notes for general corporate purposes. Citigroup Global Markets Inc., Goldman Sachs & Co. LLC , J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering. The off

    9/16/25 8:52:17 AM ET
    $CG
    Investment Managers
    Finance

    $BLUE
    $CG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by The Carlyle Group Inc.

    SC 13D/A - Carlyle Group Inc. (0001527166) (Subject)

    11/15/24 5:22:29 PM ET
    $CG
    Investment Managers
    Finance

    Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

    SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

    11/14/24 4:39:36 PM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

    SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

    11/14/24 4:27:32 PM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care